In a study of 3,278 patients with stage II and III colon cancer patients receiving irinotecan added to fluorouracil (FU)/leucovorin (FA) as adjuvant treatment, KRAS mutation did not have significant prognostic value while BRAF was prognostic for overall survival in MSI-low and stable tumors52. This evidence concerns the gene BRAF and colonic neoplasm.